South Carolina Medical Cannabis: How Federal Rescheduling Could Trigger an Obscure 1980 Law

South Carolina medical marijuana access could open up almost overnight — not through a new bill, not through Governor Henry McMaster's signature, and not through a ballot vote. Instead, two dormant statutes from 1980 and 1971 may have been quietly activated by a federal action that happened more than 600 miles away in Washington, D.C. As of early May 2026, lawyers, lawmakers, and patient advocates in the Palmetto State are scrambling to interpret what the Trump administration's medical cannabis rescheduling means for a state that has otherwise stalled out on legalization for years.

The Mirror Statute That Could Change Everything

At the heart of the story is South Carolina Code § 44-53-160(c), a "mirror" provision that requires the state to update its controlled substances schedules whenever the federal government does. The relevant language is unusually direct: when a substance is "added, deleted, or rescheduled" under federal law, state officials have 30 days to make the same change in South Carolina's "appropriate schedule." Governor McMaster's spokesperson, addressing the Charleston Post and Courier in late April, confirmed this reading.

That mechanism became consequential on April 23, 2026, when the Justice Department and DEA placed FDA-approved marijuana products and state-licensed medical marijuana products into Schedule III of the Controlled Substances Act. South Carolina's mirror statute means the state now has a narrow window to follow suit — and once it does, a separate dormant program could quietly come back online.

That program is the South Carolina Controlled Substances Therapeutic Research Act, passed in 1980. It established a state pathway for cancer and glaucoma patients to obtain medical cannabis "through whatever means" the state health commissioner "deems most appropriate consistent with federal law." For four decades, "consistent with federal law" effectively meant "not at all," because cannabis was Schedule I and federally prohibited for almost any therapeutic use. With Schedule III status, that ceiling rises substantially.

Why This Matters Now

South Carolina is one of the few remaining U.S. states without a functioning medical cannabis program. The Compassionate Care Act, championed for years by Sen. Tom Davis (R-Beaufort), has cleared the Senate multiple times but repeatedly stalled in the House. Over that stretch, neighboring North Carolina and Georgia have inched toward limited programs, while patients have crossed state lines or relied on hemp-derived alternatives sold under the 2018 Farm Bill loophole.

Now, federal rescheduling has scrambled that equilibrium. Several developments are converging at once:

The DEA's new medical marijuana registration portal opened on April 29, 2026, giving state-licensed operators a 60-day window to apply for federal protections. South Carolina has no state-licensed medical operators yet, but Schedule III pharmaceutical pathways could allow FDA-approved cannabis products — like Epidiolex and any forthcoming approvals — to flow through traditional pharmacies under the 1980 act's "consistent with federal law" language.

Patient advocacy groups have begun pressing the South Carolina Department of Health and Environmental Control (DHEC) to implement the 1980 statute's provisions for cancer and glaucoma patients. While narrow, the program offers a pre-existing legal scaffolding that wouldn't require new legislation.

Sen. Davis told reporters in late April that rescheduling "removes the federal preemption argument" that has historically been used to block a fuller medical program in South Carolina, potentially boosting the next iteration of the Compassionate Care Act.

The 1980 Act's Limits — and Possibilities

The Therapeutic Research Act is not a sweeping legalization law. It was modeled after similar 1970s and 1980s programs that allowed a small group of patients to access federally supplied cannabis as part of investigational research. Most of those programs went dormant when federal supply dried up in the 1990s.

The South Carolina version, however, was never formally repealed. With Schedule III now lowering the bar for pharmaceutical and research access, the act could theoretically allow DHEC to certify a limited number of cancer and glaucoma patients to receive cannabis-based products from federally compliant sources. Whether the agency actually moves to implement remains an open question — and DHEC has not publicly committed to a timeline.

There are practical limits. The act predates modern dispensary infrastructure. There is no licensed cultivation in South Carolina, no processing facility, no retail dispensary network, and no patient registry. Any near-term implementation would likely route patients through pharmacy fulfillment of FDA-approved cannabinoid drugs rather than through a state-grown supply chain. That distinction matters: it would not create a Massachusetts-style adult-use market, but it could meaningfully change life for terminal cancer patients seeking THC-based antiemetics.

Tennessee's Counter-Move

The South Carolina situation is not happening in a vacuum. Several other states — including Tennessee, Iowa, and Texas — also have mirror statutes or related triggers that activate when the federal schedule changes. Tennessee lawmakers, anticipating exactly this scenario, passed legislation in early 2026 to decouple state cannabis policy from federal scheduling, effectively neutralizing any automatic shift. South Carolina has no such firewall in place.

Critics of an automatic-trigger interpretation argue that § 44-53-160(c) gives state regulators discretion in how to apply the rescheduling — and that DHEC could place cannabis in a "more restrictive" state schedule even after federal Schedule III takes effect. Patient advocates counter that the statute's plain language uses the federal action as the reference point, leaving little room for restrictive workarounds.

The Political Read

McMaster, a longtime cannabis skeptic, has not offered substantive comment beyond his office's confirmation that state law "would require" the schedule change. That measured silence is notable. It does not commit the administration to expanding patient access, but it also does not foreclose the possibility — and it leaves political space for the legislature, DHEC, or the courts to drive what happens next.

Rep. Bill Sandifer (R-Oconee), who sits on the House Medical, Military, Public and Municipal Affairs Committee, told local media that the rescheduling "changes the conversation." With pharmaceutical lobbying, hospital association lobbying, and patient advocacy lobbying all pulling in slightly different directions, the calculus that has kept the Compassionate Care Act bottled up in the House may finally have shifted.

What South Carolina Patients Should Know

For South Carolina residents tracking these developments, several things are still true on May 3, 2026:

Possession of cannabis flower remains illegal under state law. Federal rescheduling did not legalize any conduct outside of FDA-approved or state-licensed channels — and South Carolina has neither.

Hemp-derived products under the 0.3% delta-9 THC threshold remain legal under the 2018 Farm Bill, though the proposed 2026 Farm Bill in Washington could narrow that pathway as soon as later this year.

Medical cards from other states are not recognized in South Carolina. Patients with Maryland, Florida, or Virginia medical cards are still subject to South Carolina possession laws when they cross the state line.

Anyone considering travel into South Carolina with cannabis products should consult current state law and a qualified attorney rather than relying on federal rescheduling as cover.

Key Takeaways

• South Carolina's § 44-53-160(c) "mirror" statute requires the state to follow federal rescheduling, giving regulators 30 days to update the controlled substances schedule.
• The 1980 South Carolina Controlled Substances Therapeutic Research Act, never formally repealed, could provide a narrow pathway for cancer and glaucoma patients now that cannabis is no longer "consistent" only with Schedule I.
• Governor McMaster's office has acknowledged the legal mechanism but has not committed to implementing the 1980 program, leaving patient access dependent on DHEC and the legislature.
• Tennessee has already passed a decoupling law to block automatic state changes; South Carolina has no such firewall, making it one of the most consequential test cases for "trigger states" post-rescheduling.
• Possession remains illegal in South Carolina under current law, and the federal action does not by itself create a regulated market or recognize out-of-state medical cards.

Explore cannabis news, find dispensaries, and join the community at Budpedia.